Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8NA66
UPID:
CNBD1_HUMAN
Alternative names:
-
Alternative UPACC:
Q8NA66
Background:
Cyclic nucleotide-binding domain-containing protein 1, identified by its unique sequence Q8NA66, plays a crucial role in cellular signaling pathways. This protein, through its cyclic nucleotide-binding domain, is pivotal in the regulation of intracellular concentrations of cyclic nucleotides, which are key signaling molecules involved in a wide range of cellular processes.
Therapeutic significance:
Understanding the role of Cyclic nucleotide-binding domain-containing protein 1 could open doors to potential therapeutic strategies. Its involvement in critical signaling pathways suggests its potential as a target for therapeutic intervention in diseases where these pathways are dysregulated.